共 107 条
[1]
Abigerges D(1995)Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J Clin Oncol 13 210-221
[2]
Chabot GG(2000)Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity J Clin Oncol 18 1116-1118
[3]
Armand JP(1996)In vivo evaluation of docetaxel-irinotecan combination Proc Am Assoc Cancer Res 37 A2578-651
[4]
Herait P(1997)Docetaxel in combination with irinotecan: prediction of clinical maximum tolerated dose Proc Am Soc Clin Oncol 16 221A-297
[5]
Gouyette A(2002)Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer Cancer Biol Ther 1 646-1219
[6]
Gandia D(2003)Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer J Clin Oncol 21 291-1487
[7]
Adjei AA(2000)Docetaxel administered on a weekly basis for metastatic breast cancer J Clin Oncol 18 1212-2655
[8]
Klein CE(1996)Response to dexamethasone in patients with fluid retention after docetaxel Lancet 347 1486-3552
[9]
Kastrissios H(1995)Docetaxel J Clin Oncol 13 2643-4354
[10]
Bissery MC(2000)Phase I and pharmacokinetic study of docetaxel and irinotecan in patients with advanced solid tumors J Clin Oncol 18 3545-656